[144/A] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filing is a Form 144/A notice reporting a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an approximate aggregate market value of $95,661.94, and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022. The filing also discloses three insider sales in the past three months by Quang X. Pham totaling 7,610 shares for gross proceeds of $106,104.20 across sales on 08/27/2025, 08/28/2025, and 09/24/2025. The notice includes the required certification that the seller is not aware of undisclosed material adverse information.

Positive

• Clear disclosure of the planned sale amount (6,790 shares), broker, estimated aggregate market value ($95,661.94), and planned sale date (09/25/2025).
• History of recent sales provided (7,610 shares sold in prior three months) with gross proceeds detailed, supporting market transparency.
• Origin of shares documented as Founders Shares acquired 01/25/2022, which clarifies the acquisition basis for Rule 144 purposes.

Negative

• Insider selling activity: planned sale plus recent sales total 13, ?400? shares (6,790 planned + 7,610 prior), representing insider liquidity rather than an acquisition signal.
• Administrative fields missing in provided excerpt: the supplied content does not show a completed date of notice or visible signature block information to fully confirm form execution in this snippet.

Insights

Securities Analyst

TL;DR: Insider disclosed planned sale of 6,790 founder shares; recent insider sales total 7,610 shares, disclosure complies with Rule 144/A requirements.

The Form 144/A shows a founder-origin position being sold through a broker with explicit quantities, values, and dates, which is standard for Rule 144 reporting. The disclosed past three months of sales by the same person (7,610 shares) and the planned 6,790-share sale are small relative to the reported outstanding shares (2,046,854), representing under 1% of outstanding stock. From a compliance and market-transparency standpoint, the filing is complete for the items provided. No earnings, financing, or other corporate developments are disclosed here to change valuation drivers.

Corporate Governance Expert

TL;DR: The filing documents insider liquidity events but does not indicate undisclosed material corporate developments.

This notice fulfills the statutory disclosure obligation for an insider sale under Rule 144. It records that the shares were originally issued as founders shares and provides broker details, sale timing, and proceeds for recent transactions. The seller's attestation regarding material adverse information is present, but the form does not include a notice date or signature block details in the provided content. That omission in the supplied text means those administrative fields cannot be independently confirmed from this excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	6790	95661.94	2046854	09/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			6790	01/25/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/24/2025	2581	36108

144/A: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Cadrenal Therapeutics (CVKD) disclose in this Form 144/A?

The filing reports a proposed sale of 6,790 common shares via Merrill Lynch on or about 09/25/2025, acquired as founders shares on 01/25/2022, plus three prior sales totaling 7,610 shares.

Who is the seller named in the filing?

The recent sales listed were by Quang X. Pham, whose address is shown in the filing; the proposed sale is identified for the account associated with that filing.

How many shares of Cadrenal are outstanding per the filing?

The filing shows 2,046,854 shares outstanding against which the disclosed sale amounts should be evaluated.

What were the proceeds from the insider sales in the past three months?

Gross proceeds totaled $106,104.20 from three sales: $53,455.56 (08/27/2025), $16,540.64 (08/28/2025), and $36,108.00 (09/24/2025).

Were the shares being sold subject to any special acquisition terms?

The shares were recorded as Founders Shares acquired from the issuer on 01/25/2022; no non-cash payment terms are indicated in the excerpt.